[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1987001938A1 - Systeme d'administration transdermique de medicaments aux liposomes - Google Patents

Systeme d'administration transdermique de medicaments aux liposomes Download PDF

Info

Publication number
WO1987001938A1
WO1987001938A1 PCT/US1986/001893 US8601893W WO8701938A1 WO 1987001938 A1 WO1987001938 A1 WO 1987001938A1 US 8601893 W US8601893 W US 8601893W WO 8701938 A1 WO8701938 A1 WO 8701938A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
matrix
liposomes
release
transdermal
Prior art date
Application number
PCT/US1986/001893
Other languages
English (en)
Inventor
Richard H. Guy
Francis C. Szoka
Victoria M. Knepp
Ronald C. Wester
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO1987001938A1 publication Critical patent/WO1987001938A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Definitions

  • the present invention relates to transdermal drug delivery devices.
  • transdermal drug delivery devices A variety of transdermal drug delivery devices have been proposed heretofore.
  • One general type of transdermal device consists of a matrix reservoir containing a drug in free form, and one or more microporous walls which limit the rate of drug diffusion out of the matrix.
  • United States Patent No. 4-,336,243 describes a nitroglycerine patch in which the drug is contained in a cross-linked silicon matrix formed of microporous, cross-linked walls.
  • the rate of drug release from the matrix is controlled by a drug release barrier placed between the matrix and skin.
  • Transdermal devices of the type just described have a number of limitations.
  • the rate of drug diffusion through the microporous wall can vary widely, depending on drug size and solubility. Therefore, considerable design work may be required to construct a diffusion barrier having desired permeability properties for a given drug. Also, where the diffusion barrier is a single membrane, small variational defects in the 5 membrane can lead to significant variations in drug release rate.
  • the devices are best suited to water-soluble drugs which can be dispersed in high concentration throughout a hydrated matrix.
  • the drug is encapsulated in microcapsules which are distributed throughout a drug matrix.
  • the icrocapsule walls are permeable to passage of the drug, and act to control the rate of drug release from the device.
  • Devices of this types are disclosed in B U.S. Patents Nos. 3,598,123, 3,797,494, and 3,464,413.
  • the drug is a water-soluble drug encapsulated in a polymer-shell microcapsule.
  • a specific object of the invention is to provide such a device for releasing a lipophilic drug at a selected, substantially constant release rate over a period of at least about 24 hours.
  • Another object of the invention is to provide a transdermal device for delivering a water-soluble drug under conditions which promote transdermal uptake of the drug.
  • Still another object of the invention is to provide a method of achieving a selected, substantially constant release rate of a lipophilic drug in a transdermal device.
  • the liposo e drug release device, or patch of the invention includes an aqueous-phase matrix having a surface adapted to be placed against the skin surface. Liposomes embedded within the matrix and containing an entrapped lipophilic drug are formulated to produce a selected, substantially constant rate of drug release for a period of at least about 24 hours.
  • the concentration of liposomes in the matrix is preferably between about 5 and 25 percent by volume, and the major portion of drug in the matrix is partitioned initially in the liposome bilayers .
  • the matrix contains a water-soluble drug in free form, and the entrapped lipophilic drug is a drug-transport agent effective to facilitate transdermal uptake of the water-soluble drug.
  • the device may include a diffusion barrier to control the rate of release of water-soluble drug from the matrix, such that both the water-soluble drug and uptake agent are delivered from the device at relatively constant, selected release rates.
  • the invention includes a method of achieving a selected, substantially constant rate of release of a lipophilic drug from an aqueous-phase matrix over a period of at least about 24 hours.
  • the method involves entrapping the drug in liposomes containing phospholipid components which are __(.-.
  • Figure 1 is a schematic sectional view of a transdermal drug delivery patch constructed according to one embodiment of the invention
  • Figure 2 is a sectional view of a transdermal drug delivery patch constructed according to another embodiment of the invention.
  • Figures 3A and 3B are, respectively, graphs of percent progesterone (PG) release per hour in a transdermal patch containing free PG, over a 24 hour period, and cumulative percent PG released from the patch over the same time period;
  • PG progesterone
  • Figures 4A and 4B are graphs showing PG released per hour and cumulative PG released, respectively, for a transdermal patch in which PG is entrapped in egg phosphatidylcholine (PC) liposomes
  • Figures 5A and 5B are graphs showing PG released per hour and cumulative PG released, respectively, for a transdermal patch in which PG is entrapped in dipalmitoyl phosphatidylcholine (DPPC) liposomes
  • Figures 6A and 6B are graphs showing PG released per hour ahd cumulative PG-released, respectively, for a transdermal patch in which PG is contained in oil emulsion particles; -5-
  • Figure 7 is a plot of the relationship between percent PG release and square root of release time for an egg PC liposome transdermal patch
  • Figures 8A and 8B are graphs showing respectively, the percent dose of PG per hour and cumulative PG delivered across full-thickness skin, for a transdermal patch in which PG is contained in free form;
  • Figures 9A and 9B are graphs showing, respectively, the percent dose of PG per hour and cumulative PG delivered across full-thickness skin, for a transdermal patch in which PG is entrapped in egg PC liposomes;
  • Figures 10A and 10B are like Figures 9A and 9B, respectively, for a patch in which PG is entrapped in DPPC liposomes.
  • the transdermal drug-release device, or patch, of the invention includes an aqueous-phase matrix, and embedded within the matrix, liposomes containing a lipophilic drug in entrapped form.
  • the liposomes are composed of lipid components and preferably phosphoiipid components which are selected to produce a desired rate of drug release from the matrix.
  • the drug-release rate is substantially constant for at least about 24 hours, and up to two weeks or more, depending on the liposome composition.
  • the lipophilic drug may be a systemically active drug which is effective at relatively low blood levels, when delivered over a prolonged period.
  • drugs include birth control steroids, such as estranol, norethynodrel, ethanyl estradiol, norgestrel, estradiol, progesterone, and norethindrone; other steroids, such as testosterone; anti-inflammatory drugs, such as cortisone and triamcinolone, analgesic drugs, such as morphine and codeine; nitrates, such as nitroglycerine and isosorbide dinitrate; anti-hypertensives, such as furosamide, chlorothiazide, inoxidil and propranol; anti-depressants, such as protriptyline; cardiovascular agents, such as quinidine, disopyramide, and clonidine; fat-soluble vitamins, such as vitamin A and D; prostaglandins; prostacyclines; and calcium channel blockers, such as nifedipine.
  • birth control steroids such as estranol, norethynodrel, ethanyl estradiol,
  • the drug may be one whose primary site of action is the site of topical administration.
  • Drugs of this type include anti-inflammatory agents, antibiotics, analgesics, and local anesthetics, such as novacaine, and lidocaine.
  • the lipophilic drug is a drug-transport agent designed to facilitate transdermal uptake of a water-soluble drug which is present in free form in the matrix and delivered from the matrix concurrently with the drug-transport agent.
  • exemplary transport agents include a variety of aliphatic, cycloaliphatic and aromatic compounds, such as those named in U.S. Patent Mo. 3,797,494.
  • One preferred type of drug-transport agent is selected from a class of azacyclo pentane- and heptane-ones, such as those disclosed in U.S. Patents Nos. 4,316,893 and 3,989,816.
  • the rate of drug release from the matrix is controlled by the rate of drug exchange between liposomes and the surrounding aqueous medium.
  • studies conducted in support of the invention, and reported in Section II below show that liposomes have the capability of releasing (exchanging) drug at a relatively constant rate, independent of liposome drug concentration, and that the rate of drug release, or exchange, can be controlled, within broad limits, by varying the lipid composition of the liposomes .
  • Partitioning of the drug between the lipid (liposome bilayer) and aqueous phase (the non-liposomal bulk aqueous phase) is determined by the lipid/aqueous partition coefficient of the drug and the volume percent of liposomes in the matrix. For example, in a device in which the liposomes constitute 10 percent of the total matrix volume, a drug having a liposome/aqueous phase partition coefficient of 1° will partition in roughly equal amounts between the liposomes and bulk aqueous phase of the matrix.
  • the partition coefficient of the drug and the volume percent of liposomes in the matrix are preferably selected to insure that at least about 50% and more preferably, 80% or more of the drug is contained in the liposomes at initial drug-release conditions. Assuming that the liposomes make up, at most, about 25% of the matrix volume, the lipophilic drug used in the invention should therefore have a partition coefficient of at least about 4.
  • the partition coefficients of many drugs have been determined for two-phase oil water solvent mixtures, such as an octanol/water mixture (see, for example, Yalkowsky, S.H., et al, Phar a. Sci. 72:866 (1983)).
  • the drug partition coefficients determined using simple oil/water mixtures are useful in comparing the relative lipophilic character of different drugs.
  • the actual partition coefficient of a drug in liposomes depends on several factors which affect the hydrophobicity of the liposome bilayer region and degree of lipid packing in the liposome bilayer.
  • progesterone PG
  • PG progesterone
  • DPPC phospholipid-chain, saturated lipid.
  • Pure phospholipids and phospholipid mixtures with a variety of acyl chain moieties are commerjcially available or can be isolated or synthesized by known methods.
  • the effect of cholesterol on drug release rate in egg PC liposomes has also been examined (Example III). Liposomes containing PC and cholesterol, at a 2:1 mole ratio, showed substantially the same PG release rate as did pure egg PC liposomes (about 1% total drug release per hour). These results are consistent with earlier studies on release of MPS from liposomes, which showed that cholesterol only slightly increased drug release in egg PC liposomes. However, the MPS studies did show that cholesterol can significantly increase drug-release in liposomes whose phospholipid components contain long-chain, saturated acyl groups.
  • the lipids forming the liposomes may, of course, include phospholipids and sterols other than the model lipids used in the above-mentioned studies and Examples, and may also include other types of lipids, such as glycolipids and sphingolipids, which are compatible with liposome formation.
  • lipids which are used commonly in liposome formation is given on page 471 of Szoka, F., Jr., et al, Ann. Rev. Biophys. Bioeng. 9:467 (1980).
  • the liposomes may also be formulated to include various types of drug-protective or lipid-protective agents, such as the antoxidant ⁇ -tocopherol, which was included at a 0.6 mole percent in the liposomes described in the examples.
  • drug-protective or lipid-protective agents such as the antoxidant ⁇ -tocopherol, which was included at a 0.6 mole percent in the liposomes described in the examples.
  • the liposomes may be prepared by a variety of techniques, such as those detailed in the above-cited - * Szoka et al reference.
  • a simple lipid-hydration procedure for producing multilamellar vesicles (MLUs) is -generally suitable. In this procedure, a mixture of vesicle-forming lipids and the drug are dissolved in a suitable organic solvent or solvent mixture, then evaporated in a vessel to form a thin film. Hydrating the thin film with an aqueous solution, over a period of at- least about 1 hour, produces multilamellar vesicles (MLUs), with sizes typically between about 0.1 to 10 microns.
  • the drug is preferably incorporated initially into the lipids forming the vesicles, as above, it may also be diffused into preformed liposomes. If necessary, the drug diffusion step can be carried out in the presence of a mild detergent, such as deoxycholate, to facilitate drug exchange with the liposomes.
  • a mild detergent such as deoxycholate
  • the detergent can be removed by dialysis after liposome uptake.
  • the amount of drug which is included in the lipid-forming vesicles is that calculated to produce a selected total drug concentration in the transdermal device.
  • the amount of drug that can be incorporated into the transdermal device is limited by the amount of drug that can be stably incorporate _d into liposomes, the maximum allowed concentration of liposomes in the matrix and patch size.
  • vesicle-forming lipids can form stable liposomes in the presence of between 1-5 mole percent drug.
  • the drug concentration can be as high as 40-50 mole percent without significant membrane instability.
  • the drug to lipid ratio can be safely increased until an increase in the rate of drug release is observed in the liposomes. The increase drug-release rate signals drug-saturation of the liposomes and membrane instabilit .
  • the maximum concentration of liposome which can be embedded in the matrix will depend on the nature of the material forming the matrix and the method of matrix formation. Generally, the concentration of liposomes in the matrix will be between about 5% and 25% based on the total liposome volume per total matrix volume.
  • the matrix can be formed of any dermatolgically acceptable gel or cross-linked polymer material which is compatible with an aqueous medium, and capable of gelling or forming cross links under conditions, particularly temperature conditions, which do not disrupt liposomes.
  • a variety of polymers and polymer mixtures, which are suitable are listed in U.S. Patent No. 3,797,494, columns 14 and 15. Also disclosed in this patent are a number of gel-forming polymers, such as cellulose derivatives, which are useful in forming the matrix.
  • One preferred matrix material used in the device described in Examples II-IU is the polysaccharide agarose.
  • the cross-linking step may involve adding a chemical catalyst, and/or ight-induced cross-linking.
  • an acrylamide polymer matrix can be formed by cross-linking acrylamide, either by addition of a free-radical generator such as ammonium persulfate, or by light-induced cross-linking in the presence of a photosensitizer such as riboflavin. Methods for cross-linking polymers under suitable temperature conditions are well known.
  • A.gel matrix is formed typically by heating gel material in an aqueous medium to its solution temperature, cooling the solution to somewhat above its gelling temperature then mixing the material with a selected volume of liposome suspension.
  • concentration of the gelled material is selected to provide a relatively firm, shape-retaining structure after dilution with the liposome suspension.
  • the final gel concentration is between about l%-5% w/v .
  • the iposome/gel material is poured into a mold and cooled to form the matrix.
  • Example II below describes the preparation of liposome patches by mixing a 4% agarose solution at 67°C with an equal volume of liposome suspension and allowing the mixture to gel by slow cooling.
  • FIG. 1 is a schematic, sectional view of a liposome drug-delivery device 10 prepared according to the invention.
  • An aqueous-phase matrix, indicated at 12 contains liposomes, such as those shown at 14, embedded throughout. The liposomes serve as a reservoir for a lipophilic drug, a portion of which is available in free form, as indicated at 18.
  • the lower surface of the matrix in the figure defines a drug-release surface 20 adapted to be placed against a skin surface for transdermal drug delivery.
  • the upper surface is sealed with an impermeable cover 22.
  • the cover extends beyond the edges of the matrix, and is adhesive backed in its extending edge regions, allowing the device to be adhesively attached to a skin surface.
  • FIG. 2 An alternative embodiment of the invention, for use in delivering a water-soluble drug, is illustrated at 24 in Figure 2.
  • this device releases both a water-soluble drug, which is contained in free form in the matrix, and a lipophilic drug-transport agent of the type mentioned above, which acts to increase transdermal uptake of water-soluble molecules.
  • the transport agent is contained in liposomes, such as those at 26, and these are embedded in an aqueous-phase matrix 28, as in device 10 above.
  • the device is formed as above, except that the water-soluble drug, indicated at 29, is included in the polymer or gel material used in forming the matrix.
  • Exemplary water-soluble drugs include antihisti ines, such dimenhydrinate, diphenhydramine, chlorpheniramine, and ephidrin; anti-motion drugs, such as scopolamine; antibiotics, such as penicillin; and tranquilizers and other nervous disorder drugs, such as dopa.
  • antihisti ines such dimenhydrinate, diphenhydramine, chlorpheniramine, and ephidrin
  • anti-motion drugs such as scopolamine
  • antibiotics such as penicillin
  • tranquilizers and other nervous disorder drugs such as dopa.
  • Device 24 has a cover 30 protecting its upper surface against dehydration, and also has a diffusion-barrier membrane 32 covering its lower drug-release surface.
  • Membrane 32 functions to limit the rate of release of the water-soluble drug from the atrix, preferably at a release level which is compatible with the release rate of the lipophilic drug-transport agent.
  • the diffusion-limiting membranes described in U.S. Patents Nos. 4,286,592; and 3,598,123, for use in limiting the rate of passage of water-soluble membranes are generally suitable.
  • FIG. 3A shows the levels of drug release from the free-drug patch measured at 1 hour intervals over a 24 hour period, where the radioactivity measured at each time point is expressed as percent of total radioactivity in the patch.
  • Drug release characteristics of a liposome patch prepared with egg PC lipids are shown in Figure 4A and 4B.
  • the liposome patch released progesterone at a substantially constant release rate of about 1 percent total drug per hour over the 24 hour test period.
  • the plot of cumulative amount released over the 24 hour period shows a substantially linear increase in released PG over 24 hours, to about 25% of total drug.
  • Drug-release measurements on the egg PC/cholesterol patch, taken every hour over a 48 hour test period were similar to those for egg PC liposomes. The rate of drug release was 1% per hour over the test period, and about half the drug was released in 48 hours.
  • the drug release characteristics of the the DPPC liposome patch were also measured over a 48 hour period, with the results shown in Figures 5A and 5B.
  • the percent dose release every hour, plotted in Figure 4-A remained substantially constant, at between about 0.15 and 0.2 percent total drug, over the entire test period.
  • the cumulation of drug dose, plotted in Figure 5B shows that (a) the drug accumulates in a linear fashion, and (b) the rate of accumulation is about 4% total PG every 24 hours.
  • the drug accumulation rate is that seen for both the egg PC and egg PC/cholesterol liposome patches .
  • the drug release and accumulation characteristics of a lipid emulsion patch are graphed in Figures 6A and 6B, respectively.
  • the drug release rate was substantially constant at about 2.5% per hour, for the first 8-10 hours, then declined to about 1% per hour after 24 hours.
  • the released drug reached an accumulated level of about 30% of total drug during the first 12 hour period of linear drug release, and a final accumulated drug level of about 50% after 24 hours.
  • the error bars are standard deviations for 5-6 individual tests.
  • Figure 8A shows the levels of PG delivered transdermally into the lower reservoir from the free-drug patch, measured at 1 hour intervals over a 48 hour period.
  • the radioactivity measured at each time point is expressed as percent total radioactivity in the patch.
  • the amount of drug penetrating the skin barrier reached a maximum of about 0.4%-0.5% within 6-8 hours, and remained at this level throughout the test period (only the first 40 hours of the test period are shown) .
  • the skin sample variation in drug-release rates is indicated by the standard deviation bars in the figure.
  • the curve in Figure 8B is obtained, showing that about 25% of the total drug penetrated the skin barrier in the 48-hour test period.
  • the rate of transdermal PG uptake when the drug is released from an egg PC liposome patch, is shown in Figure 9A.
  • the rate of drug transport across the skin reached a level of about 0.2% per hour within about 16 hours, then substantially plateaued over the next 40 hours.
  • the plot of accumulated drug over time ( Figure 9B), when extrapolated to 48 hours, showed that about 10% of the total drug was delivered over a 2-day period.
  • the liposome patch thus modulates, by a factor of 2-3, the rate of transdermal drug uptake, compared with a diffusion-limited (free-drug) transdermal device.
  • FIGS 10A and 10B which plot transdermal uptake characteristics observed with a DPPC liposome patch.
  • Figure 10A shows that transdermal uptake increased over the first 8-16 hours, then plateaued over the next 24 hours at about 0.03% per hour, with a standard deviation of about .01% total dose. Total drug uptake was about 1.35% after 48 hours
  • the results of the transdermal uptake studies are summarized in Table II below.
  • the drug transport rate is the steady-state level observed after several hours, and the standard deviation is an approximate average of the standard deviation observed during the steady-state period.
  • the roughly five-fold difference in drug transport rates between the egg PC and DPPC patches is consistent with the difference in the drug-release rates (Table I) between the two patches.
  • the ability of the liposome transdermal patch to control drug bioavailability in vivo has been confirmed in tests with rhesus monkeys.
  • the tests were designed to determine estradiol transdermal bioavailability by cumulative tuition excretion following drug administration.
  • the drug/liposome patch was applied for either 24 or 48 hours.
  • the bioavailability was about 1% total drug for the 24 hour application and roughly twice that for the 48 hour application. In both cases, the drug level remained constant for 24 hours after the patch was removed.
  • the same quantity of drug administered topically in free form gave about 10% drug level after 24 hours and the drug level fell rapidly during the 24-48 hour period.
  • the liposome patch is easily constructed and the lipid and matrix components are stable for periods of several months or more under suitable storage conditions.
  • the liposome system can be readily adapted to deliver any relatively stable, lipid-compatible lipophilic drug, and the drug release rate can be readily adjusted by appropriate selection of liposome lipid components and liposome concentration.
  • the salt concentration of the aqueous medium can also be adjusted to alter the partitioning of the drug in the matrix. Since the drug-release rate is largely dependent on drug partitioning across a liposome/water interface, rather than on drug concentration within the liposomes, the device can be designed to produce a controlled, substantially constant rate of drug release over an extended period. The studies on the DPPC liposome device indicate that a constant drug release for up to 2 weeks is possible. Further, the total amount of drug released, at a selected drug release rate, is easily varied by varying drug concentration in the liposomes or the volume of the patch.
  • the device is able to modulate the rate of drug transport through skin, and the data in Table II indicates that the extent of modulation can be controlled over at least a five-fold range, by selected changes in liposome composition.
  • Phospholipids at greater that 99% purity, were obtained from Sigma Chem Co (St. Louis, MO); cholesterol, from Sigma Chemical Co. (St. Louis, MO), and C 14-labeled Progesterone (PG).
  • INTRALIPID was supplied by Cutter Labs (Berkeley, CA) .
  • GELBOND backing, an impermeable membrane, and agarose were obtained from FMC Corporation (Rockland, ME).
  • Example I Drug/Lipid Preparations Lipid solutions containing either (a) pure egg PC, (b) egg PC;cholesterol, at a mole ratio of 2:1, or (c) pure DPPC were prepared to a final lipid concentrations of about 100 mg/ml in chloroform. Each of the solutions (2.5 ml) was combined with about 0.4 ⁇ Ci C 14PG in a round bottom flask and the mixture dried to a film under vacuum.
  • citrate buffered saline pH 4.5
  • lipid/ml 14 63 mg lipid/ml, and a final C PG concentration of about 0.1 ⁇ Ci/ml.
  • the lipid films were hydrated by gentle swirling for one hour at 37°C to form suspensions of multilamellar vesicles (MLUs) .
  • the suspensions are designated egg PC, egg PC/cholesterol, and DPPC, according to their lipid composition.
  • INTRALIPID an emulsion of soybean oil in a physiological salt solution, was concentrated to 22 mg lipid/ml.
  • C 14PG was added to the concentrated emulsion to a final concentration of about 0.5 ⁇ Ci/ml.
  • Transdermal Patches A suspension of agarose in citrate-buffered saline, pH 4.5, was solubilized by heating, then cooled to 67°C.
  • - Transdermal liposome patches were prepared by mixing equal volumes of 4% agarose at 67°C and a selected MLU suspension from Example I, and pouring about 1 ml of the warm mixture into a 5 cm square mold. The bottom of each mold was covered with a 16 cm square piece of GELBOND membrane, with the hydrophilic side of the membrane facing up. The agarose-lipid mixture was allowed to gel by cooling to room temperature.
  • Each patch had a final thickness of about 1.5 mm, and contained a total of about 40 ⁇ Ci C 14 PG.
  • An INTRALIPID PATCH was similarly prepared by mixing 0.9 ml of agarose and 0.12 ml of INTRALIPID to a final agarose concentration of about 2%.
  • the patch contained 38-40 ⁇ mole lipid and 0.05 ⁇ Ci C 14 PG.
  • a transdermal patch containing free PG only (nonlipid patch) was prepared by mixing the warm 4% agarose from above with an equal volume of PG in citrate-buffered saline (0.1 ⁇ Ci/ml) . The mixture was poured into a mold and cooled, as above.
  • Example III Direct Drug-Release Rates: Lipid vs Nonlipid Patches The rates of drug release from the lipid and nonlipid patches prepared in Example II were measured in a standard glass diffusion cell of the type having separable, confronting chambers. The transdermal patch being tested was placed in the upper chamber, with its free surface facing inwardly.
  • the lower chamber which served as a liquid reservoir for receiving drug released from the patch, was provided with opposite-side ports for flowing receptor liquid through the lower chamber.
  • the lower cell was filled with citrate-buffered saline until the free (inwardly facing) side of the patch was completely covered with the reservoir solution.
  • Fresh reservoir solution was flowed through the lower reservoir at about 10 ml/hr, over a 24-48 hour period.
  • the rate of release of radioactive PG was determined by measuring the radioactivity in the 10 ml fractions collected every hour, over a 24 hour period. The samples were counted by standard scintillation counting methods.
  • Figures 8B-10B show the corresponding cumulative drug doses transported through the skin for the three patches studied.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dispositif de libération transdermique de médicaments destiné à libérer un médicament lipophile physiologiquement actif à travers la surface de la peau selon un débit choisi substantiellement constant pendant une période d'au moins 24 heures environ. Ledit dispositif comprend une matrice à phase aqueuse présentant une surface conçue de manière à pouvoir être placée contre la surface de la peau et des liposomes incorporés dans la matrice contenant le médicament sous une forme occluse et composé de composants lipides choisis de manière à produire ledit débit de libération du médicament. Selon un des modes de réalisation, la matrice contient un médicament soluble à l'eau sous une forme libre et le médicament lipophile occlus est un agent de transport de médicament destiné à faciliter l'absorption transdermique du médicament soluble à l'eau.
PCT/US1986/001893 1985-09-27 1986-09-11 Systeme d'administration transdermique de medicaments aux liposomes WO1987001938A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78114785A 1985-09-27 1985-09-27
US781,147 1985-09-27

Publications (1)

Publication Number Publication Date
WO1987001938A1 true WO1987001938A1 (fr) 1987-04-09

Family

ID=25121837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/001893 WO1987001938A1 (fr) 1985-09-27 1986-09-11 Systeme d'administration transdermique de medicaments aux liposomes

Country Status (3)

Country Link
EP (1) EP0238554A4 (fr)
JP (1) JPS63501289A (fr)
WO (1) WO1987001938A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
EP0737052A1 (fr) * 1993-12-30 1996-10-16 Robert B. Royds Systeme d'administration transdermique de medicament
WO1997038677A2 (fr) * 1996-04-18 1997-10-23 Mehl Thomas L Sr Systeme d'administration de liposomes lyophilises destine a l'application d'agents de traitement de la peau
WO1998003156A2 (fr) * 1996-07-22 1998-01-29 Resource Medical Limited Composition a application topique d'hormonotherapie substitutive
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US7175850B2 (en) 1998-12-23 2007-02-13 Idea Ag Formulation for topical non-invasive application in vivo
WO2013171131A1 (fr) * 2012-05-14 2013-11-21 Sequessome Technology Holdings Ltd Formulations vésiculaires, leurs utilisations et procédés
US9452179B2 (en) 2009-08-21 2016-09-27 Sequessome Technology Holdings Limited Vesicular formulations
US9555051B2 (en) 2012-03-29 2017-01-31 Sequessome Technology Holdings Limited Vesicular formulations
US20170304260A1 (en) * 2014-10-08 2017-10-26 Maamar Achacha Altrenogest formulation and uses thereof for estrus synchronisation in animals
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617186A (en) * 1984-12-28 1986-10-14 Alcon Laboratories, Inc. Sustained release drug delivery system utilizing bioadhesive polymers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 102, No. 9, issued 04 March 1985 (Columbus, Ohio, USA), KROWCZYNSKY, "Liposomes as Drug Carriers in Transdermal Therapy," see page 355, the Abstract No. 102: 84351a, Pharmazie. 1984, 39 (9), 627-9 (Ger). *
CHEMICAL ABSTRACTS, Volume 104, No. 3, issued 20 January 1986 (Columbus, Ohio, USA), KOMATSU, "Preparation of Drugliposome Inclusion Comounds", see page 300, the Abstract No. 104: 24197m, Jpn. Kokai Tokkyo Koho Jp 60, 152, 410 (85, 152, 410) 10 August 1985. *
See also references of EP0238554A4 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US6183451B1 (en) 1991-05-30 2001-02-06 Thomas L. Mehl, Sr. Method of delivery of skin treatment agents using freeze-dried liposomes
EP0737052A1 (fr) * 1993-12-30 1996-10-16 Robert B. Royds Systeme d'administration transdermique de medicament
EP0737052A4 (fr) * 1993-12-30 1997-10-15 Robert B Royds Systeme d'administration transdermique de medicament
WO1997038677A3 (fr) * 1996-04-18 1997-12-11 Thomas L Mehl Sr Systeme d'administration de liposomes lyophilises destine a l'application d'agents de traitement de la peau
WO1997038677A2 (fr) * 1996-04-18 1997-10-23 Mehl Thomas L Sr Systeme d'administration de liposomes lyophilises destine a l'application d'agents de traitement de la peau
WO1998003156A3 (fr) * 1996-07-22 1998-03-19 Resource Medical Ltd Composition a application topique d'hormonotherapie substitutive
WO1998003156A2 (fr) * 1996-07-22 1998-01-29 Resource Medical Limited Composition a application topique d'hormonotherapie substitutive
US7175850B2 (en) 1998-12-23 2007-02-13 Idea Ag Formulation for topical non-invasive application in vivo
US9452179B2 (en) 2009-08-21 2016-09-27 Sequessome Technology Holdings Limited Vesicular formulations
US9555051B2 (en) 2012-03-29 2017-01-31 Sequessome Technology Holdings Limited Vesicular formulations
WO2013171131A1 (fr) * 2012-05-14 2013-11-21 Sequessome Technology Holdings Ltd Formulations vésiculaires, leurs utilisations et procédés
US20170304260A1 (en) * 2014-10-08 2017-10-26 Maamar Achacha Altrenogest formulation and uses thereof for estrus synchronisation in animals
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions
US11547665B2 (en) 2015-06-30 2023-01-10 Sequessome Technology Holdings Limited Multiphasic compositions

Also Published As

Publication number Publication date
JPS63501289A (ja) 1988-05-19
EP0238554A4 (fr) 1987-10-27
EP0238554A1 (fr) 1987-09-30

Similar Documents

Publication Publication Date Title
Jantzen et al. Sustained-and controlled-release drug delivery systems
AU612360B2 (en) Transdermal therapeutic systems for active ingredient combinations
Ranade Drug delivery systems. 6. Transdermal drug delivery
US5641504A (en) Skin permeation enhancer compositions using glycerol monolinoleate
US5314694A (en) Transdermal formulations, methods and devices
EP0764020B1 (fr) Systeme d'administration transdermique de medicaments
KR900005254B1 (ko) 다구획화된 피부 및 경피용 패치
US4758434A (en) Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant
JP2827217B2 (ja) 経皮吸収用製剤
Babu et al. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems
Murthy et al. Topical and transdermal drug delivery
US20110178044A1 (en) Transdermal administration of hydrophilic drugs using permeation enhancer composition
US4968539A (en) Liquid crystal membrane
GB2093694A (en) Dosage form for coadministering drug and percutaneous absorption enhancer
JPH0684304B2 (ja) チモロール用経皮的系
KR100383252B1 (ko) 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
PT100502A (pt) Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
WO1987001938A1 (fr) Systeme d'administration transdermique de medicaments aux liposomes
KR960005148B1 (ko) 활성 물질의 국소적 또는 전신적 투여를 위한 약물의 단계 방출형 경피 투여 시스템
EP0144486A2 (fr) Composition pharmaceutique à libération contrôlée et sa méthode de préparation
US6238693B1 (en) Transdermal administration of fenoldopam
JPS61268631A (ja) 経皮吸収性を高めた皮膚外用剤
WO1989004179A1 (fr) Formulations pharmaceutiques pour administration transcutanee
CA2020563A1 (fr) Formules topiques
Banker et al. Sustained-and Controlled-Release Drug-Delivery Systems

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1986905653

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1986905653

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1986905653

Country of ref document: EP